Novartis AG to Acquire Regulus Therapeutics Inc. in a Landmark Deal

In a significant move that could reshape the biopharmaceutical landscape, Novartis AG has entered into an agreement to acquire Regulus Therapeutics Inc. The deal, valued at up to $1.7 billion, marks a pivotal moment for both companies.

Initial Payment and Future Milestones: Novartis will commence with an initial payment of $7.00 per share, totaling $0.8 billion. Additionally, Regulus shareholders are set to receive a contingent value right (CVR) that promises an extra $7.00 per share, contingent upon the regulatory approval of farabursen, Regulus' lead product candidate.

A Shared Vision for the Future: "We are thrilled to join forces with Novartis to potentially deliver farabursen to patients suffering from ADPKD, a condition with currently limited treatment options," stated Regulus CEO Jay Hagan. "Novartis' global development and commercial expertise will be instrumental in bringing this vital new medicine to those in need, pending approval."

The acquisition is pending standard closing conditions and regulatory approvals, with an anticipated completion date in the latter half of 2025.